whilst a number of exploratory discussions had taken place, the company was
considering its strategy in the light of recent developments, and no firm offer was
expected any time soon.
3. Vaccination proof
The Commission presented the proposal for a single vaccine identifies with minimal data
sets. The approach was centred on health and was not linked to any use that such proof of
vaccination could have.
Some MSs took the floor to support of this idea.
One MS highlighted (i) that several MSs were already working on certificates, (ii) the
need to assess feasibility vs current stage of developments and (iii) wished to receive
details.
4. COVAX
The Commission debriefed the Members on the first meeting of the subgroup on
donations that discussed technical arrangements on how to organise reselling and
donation from the supply side.
During this meeting it was outlined that:
COVAX remained the main instrument for access to vaccines for low, medium
income countries;
donations in kind were not meant to replace COVAX but bridge the gap until
COVAX was in the position to supply in Q2 of next year;
EU may be sharing a part of its vaccines purchased jointly through APAs at the
same time they are delivered here, as an expression of solidarity;
the aim was not to
, but rather a
temporary arrangement sharing vaccines at the same time and until COVAX
delivers.
a list of 3 priority groups was established:
1)
.
During the meeting, there was a consensus on a concept note proposed by one MS.
The next meeting will go through the practical arrangements and discuss the way
forward.